^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Lung Cancer

    Related cancers:
    1d
    Preliminary Evaluation of a Large Language Model-Based Tool for Complex Surgical Decision Support in Lung Cancer (clinicaltrials.gov)
    P=N/A, N=12, Enrolling by invitation, Peking University People's Hospital
    New trial
    1d
    REHABIM: Impact of Respiratory Rehabilitation on Quality of Life in Patients With Metastatic Non-small Cell Lung Cancer Treated With Immunotherapy and Chemotherapy in the Maintenance Phase (clinicaltrials.gov)
    P=N/A, N=96, Recruiting, University Hospital, Brest | Not yet recruiting --> Recruiting | Trial completion date: Mar 2029 --> Nov 2028 | Trial primary completion date: Mar 2029 --> May 2028
    Enrollment open • Trial completion date • Trial primary completion date • HEOR
    1d
    IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE) (clinicaltrials.gov)
    P2, N=70, Recruiting, Innate Pharma | Trial completion date: Sep 2026 --> Jun 2027 | Trial primary completion date: Jun 2025 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • KRAS mutation • EGFR mutation • ALK mutation
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay • PD-L1 IHC 28-8 pharmDx
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • IPH5201
    1d
    PulmoPrint: In-vivo Fluorescence Molecular Bronchoscopy of Dur-valumab-680LT in Patients With Unresectable Stage III NSCLC After Chemoradiation (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, University Medical Center Groningen
    New P2 trial
    |
    Imfinzi (durvalumab)
    1d
    A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=36, Not yet recruiting, Sichuan Baili Pharmaceutical Co., Ltd.
    New P2 trial
    |
    Tecentriq (atezolizumab)
    1d
    SPORT-SNACC: Surgery Plus Postoperative Radiotherapy for T4 Sinonasal Adenoid Cystic Carcinoma: A Prospective Observational Study (clinicaltrials.gov)
    P=N/A, N=70, Recruiting, Eye & ENT Hospital of Fudan University
    New trial
    1d
    CHORUS: A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer (clinicaltrials.gov)
    P2, N=41, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • albumin-bound paclitaxel • Ilaris (canakinumab)
    1d
    REZILIENT1: A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=284, Active, not recruiting, Cullinan Therapeutics Inc. | Trial completion date: Mar 2026 --> Mar 2028 | Trial primary completion date: Jan 2026 --> Oct 2025
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    zipalertinib (CLN-081)
    1d
    FAHIC-Lung: A Study to Investigate the Family History of Cancer in Patients With Non-small Cell Lung Cancer (FAHIC - Lung). (clinicaltrials.gov)
    P=N/A, N=336, Completed, Fondazione Policlinico Universitario Campus Bio-Medico | Recruiting --> Completed | N=180 --> 336
    Trial completion • Enrollment change
    |
    BRAF (B-raf proto-oncogene)
    1d
    Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=120, Recruiting, Pharmacosmos A/S | Not yet recruiting --> Recruiting | Initiation date: Mar 2026 --> Jun 2026
    Enrollment open • Trial initiation date
    |
    Cosela (trilaciclib)
    1d
    ADX-MRD-LC: A Study of Molecular Residual, Dynamic Monitoring and Recurrence of Stage III Driver Mutated NSCLC (clinicaltrials.gov)
    P=N/A, N=305, Active, not recruiting, Shanghai Chest Hospital | Recruiting --> Active, not recruiting | Trial completion date: Mar 2026 --> Dec 2027 | Trial primary completion date: Mar 2025 --> Dec 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    1d
    The anti-lung cancer effect of ethyl acetate extract from Wenxia Formula in vivo via the Hedgehog-Gli1 signaling pathway mediated by cancer associated fibroblasts. (PubMed, Arch Med Sci)
    Western blot and qRT-PCR showed that WFEA extract reduced the expression of related proteins and genes (Smo, Gli1 and Ptch1) in the Hh-Gli1 signaling pathway. WFEA extract had a certain inhibitory effect on lung cancer, and its mechanism may be related to the CAF mediated Hh-Gli1 signaling pathway.
    Preclinical • Journal
    |
    PTCH1 (Patched 1) • CDH1 (Cadherin 1) • CDH2 (Cadherin 2)